Prion diseases are characterized by the conformational transition of the cellular prion protein (PrP C ) into an aberrant protein conformer, designated scrapie-prion protein (PrP Sc ). A causal link between protein misfolding and neurodegeneration has been established for a variety of neurodegenerative disease, such as Alzheimer's disease, Parkinson's disease and polyglutamine diseases, but there is an ongoing debate about the nature of the neurotoxic species and how non-native conformers can damage neuronal populations. PrP is normally imported into the endoplasmic reticulum (ER) and targeted to the outer leaflet of the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor. However, several conditions, such as ER stress or some pathogenic mutations in the PrP gene, can induce the mislocalization of PrP in the cytosol, where it has a neurotoxic potential as demonstrated in cell culture and transgenic mouse models. In this review we focus on intrinsic factors and cellular pathways implicated in the import of PrP into the ER and its mistargeting to the cytosol. The findings summarized here not only reveal a complex regulation of the biogenesis of PrP, but also provide interesting new insight into toxic activities of pathogenic protein conformers and quality control pathways of ER-targeted proteins.
Introduction
Prion diseases are a group of transmissible neurodegenerative disorders including Creutzfeldt-Jakob disease (CJD) and Gerstmann-Sträussler-Scheinker syndrome (GSS) in humans, scrapie in sheep and goat, bovine spongiform encephalopathy (BSE) in cattle and chronic wasting disease (CWD) in free-ranging deer. A hallmark of prion diseases is the conversion of the cellular prion protein PrP C into its misfolded isoform, termed PrP Sc . Similarly to other neurodegenerative diseases, there is an ongoing debate whether folding intermediates, oligomers, amorphous or fibrillar aggregates are the neurotoxic species (rev. in (Caughey and Lansbury, 2003; Haass and Selkoe, 2007; Winklhofer et al., 2008) . A unique feature of prion diseases is their transmissibility, which is also linked to PrP Sc constituting the main component of infectious prions (reviewed in Aguzzi and Polymenidou, 2004; Chesebro, 2003; Collinge, 2001; Prusiner et al., 1998; Weissmann et al., 1996) . In the majority of prion diseases there is a correlation between the accumulation of misfolded PrP, formation of infectious prions and neurodegeneration, however, there are some interesting exceptions. Transgenic mouse models revealed that several PrP mutants can induce neuronal cell death in the absence of infectious prion propagation (Baumann et al., 2007; Chiesa et al., 1998; Flechsig et al., 2003; Hegde et al., 1998; Li et al., 2007; Ma et al., 2002; Muramoto et al., 1997; Shmerling et al., 1998) . Vice versa it has been shown that propagation of infectious prions can occur in the absence of clinical signs Chesebro et al., 2005; Mallucci et al., 2003) . Consequently, it appears plausible that the infectious particle and the neurotoxic agent might be two distinct species/conformers. In this review we focus on a specific class of pathogenic PrP conformers that are characterized by a toxic potential in the cytosolic compartment. We summarize our current knowledge about PrP domains and cellular pathways regulating the translocation of PrP into the ER and pathophysiological consequences of PrP accumulation in the cytosol. corroborated these findings and provided the first evidence that information in the C-terminal domain of PrP is necessary and sufficient for ER import (Heske et al., 2004 ) (see below).
Quality control of secretory proteins
As outlined above, alterations in protein folding, processing and/or degradation are common features of prion diseases as well as other neurodegenerative disorders, implying a role of quality control systems, such as molecular chaperones and the ubiquitin-proteasome pathway in the removal of neurotoxic protein conformers (rev. in (Ciechanover and Brundin, 2003; Morimoto, 2008) . In the cytosol the ubiquitin-proteasome system (UPS) is the main pathway for regulated protein turnover (rev. in (Ciechanover et al., 2000; Hershko and Ciechanover, 1998; Pickart, 2001) . Moreover, the proteasome mediates post-translational degradation of non-native proteins generated in the ER as part of a quality control system, designated ER-associated degradation (ERAD). This pathway involves recognition of non-native polypeptides by ER-resident chaperones and retrograde transport to the cytosol where proteasomal degradation occurs (rev. in (Ellgaard and Helenius, 2003; Meusser et al., 2005; Nakatsukasa and Brodsky, 2008) . In case ERAD substrates accumulate in the ER lumen, intracellular signaling pathways are induced, collectively called the unfolded protein response (UPR) (rev. in (Malhotra and Kaufman, 2007; Ron and Walter, 2007) . Only little is known about quality control pathways of GPI-anchored proteins, such as PrP. Interestingly, a pre-emptive, co-translocational quality control pathway was described recently, which operates before translocation into the ER is completed (Kang et al., 2006; Oyadomari et al., 2006) . Regulated translocation could act as an early quality control step to prevent an overload of the ER with non-native proteins, specifically during an imbalance in cellular homeostasis. Indeed, it has been shown that PrP can be co-translocationally re-directed to proteasomal degradation during conditions of acute ER stress (Kang et al., 2006; Orsi et al., 2006) .
Import of PrP into the endoplasmic reticulum: the role of PrP domains
The N-terminal ER signal sequence The primary signal to target PrP to the ER is a N-terminal signal sequence (aa 1-22), which is recognized and bound by the signal recognition particle (SRP). SRP interaction with both the emerging polypeptide chain and the ribosome results in pausing of elongation and targeting of the ribosome-nascent chain complex to the Sec61 translocon. After binding of SRP to its receptor at the ER membrane, protein synthesis proceeds and transfer of the polypeptide chain into the ER lumen occurs in a co-translational manner (Gilmore et al., 1982a; Gilmore et al., 1982b; Meyer and Dobberstein, 1980; Walter and Blobel, 1980; Walter and Blobel, 1982; Walter et al., 1984) .
ER import can be mediated by a remarkably diverse set of signal sequences, and it has been demonstrated for various secretory pathway proteins that translocation efficiency is regulated in a signal peptide sequence-specific manner (rev. in (Hegde and Bernstein, 2006; Martoglio and Dobberstein, 1998; von Heijne, 1985) . Indeed, the sequence of the ER signal peptide has a significant impact on the import efficiency and the formation of topological isoforms of PrP. The first hint that PrP can be synthesized in topologies others than the GPI-anchored form emerged from in vitro studies . Two different topologies, termed Ntm PrP (N-terminus facing the ER lumen) or Ctm PrP (C-terminus facing the ER lumen) were described with the internal hydrophobic (HD) domain (amino acids 112 -135) serving as a putative transmembrane domain. Mutations within the internal HD or the N-terminal signal peptide were found to alter the relative amount of Ctm PrP and Ntm PrP (Hegde et al., 1998; Kim et al., 2001; Stewart et al., 2001) . Interestingly, increased synthesis of Ctm PrP has been shown to coincide with progressive neurodegeneration both in Gerstmann-Sträussler-Scheinker syndrome (GSS) patients with an A117V mutation and in transgenic mice carrying a triple mutation within the hydrophobic domain (AAA113,115,118VVV, in short AV3) (Hegde et al., 1998; Stewart et al., 2005) . For a more detailed description of Ctm PrP and other neurotoxic PrP mutants, please see the review by Harris and colleagues in the same issue.
The role of the ER signal sequence and the HD in the ER import efficiency of PrP was further emphasized when we expressed mammalian PrP in Saccharomyces cerevisiae. Due to the relatively low hydrophobicity index (Kyte-Doolittle) of the signal peptide, PrP was targeted to the ER via a post-translational pathway in yeast cells . As a consequence, ER import was impaired and the accumulation of PrP in the cytosol interfered with cell viability. By using a more hydrophobic signal peptide or by deleting the HD, import of PrP into the ER as well as and yeast growth could be restored .
The internal hydrophobic domain (HD)
The internal HD (aa 112-135) of PrP was first described as a putative transmembrane domain . Later it was shown that mutations within the HD can alter the relative amount of Ctm PrP and Ntm PrP (Hegde et al., 1998; Kim et al., 2001; Stewart et al., 2001) . Moreover, different models revealed that this stretch of hydrophobic amino acids has additional properties: 1. Short peptides comprising amino acid residues 106-126 form fibrils in vitro and induce cell death in cultured cells (Brown et al., 1996; Deli et al., 2000; Forloni et al., 1993; Haïk et al., 2000) . 2. In polarized cells the HD confers basolateral sorting in a dominant manner (Uelhoff et al., 2005) . 3. Transgenic mice expressing PrP mutants lacking the HD (PrP∆HD) spontaneously develop a non-transmissible neurodegenerative disease (Baumann et al., 2007; Li et al., 2007; Shmerling et al., 1998) . 4. The HD is linked to the toxic activity of cytosolically localized PrP (Rambold et al., 2006 ) (see below). Moreover, we have recently shown that the HD promotes dimer formation of PrP, which is associated with its stress-protective activity (Rambold et al., 2008) .
The C-terminal GPI signal peptide
Biochemical studies using purified PrP Sc revealed that PrP is modified with a glycosylphosphatidylinositol (GPI) anchor (Stahl et al., 1987) . GPI modification occurs in the ER via removal of a C-terminal signal peptide and the replacement with a pre-formed GPI anchor at an acceptor amino acid, called ω site. This reaction is catalyzed by a transamidase that resides within the ER membrane Eisenhaber et al., 1998; Englund, 1993; Udenfriend and Targeting of the Prion Protein to the Cytosol 111 Kodukula, 1995) . Similarly to the N-terminal signal peptides, the C-terminal GPI anchor signal sequences do not share conserved consensus sequences but rather characteristic features. Only a few amino acids with small side chains are allowed at the ω, the ω+1 and the ω+2 positions, and a hydrophobic domain is required about 10-12 amino acids distal to the ω site (Ferguson and Williams, 1988; Kodukula et al., 1993; Moran et al., 1991; Nuoffer et al., 1993; Nuoffer et al., 1991) .
Deletion of the C-terminal GPI anchor signal sequence prevents membrane attachment of PrP∆GPI (also known as PrP-S230X or GPI -PrP), but does not interfere with ER import or further trafficking of PrP∆GPI through the secretory pathway (Blochberger et al., 1997; Rogers et al., 1993; Winklhofer et al., 2003) . PrP∆GPI is secreted both by cultured cells and by neurons of transgenic mice (Chesebro et al., 2005) . However, membrane anchoring of PrP, be it via the authentic GPI anchor or via a heterologous CD4 transmembrane domain is required to ensure efficient modification of PrP with N-linked glycans of complex structure .
Interestingly, the C-terminal GPI anchor signal peptide has been reported to mediate targeting of PrP to the ER. Initial results obtained in vitro indicated that the C-terminal signal peptide can promote post-translational translocation of PrP into the ER (Holscher et al., 2001 ). These findings were recently corroborated in cultured cells, moreover, it was shown that the GPI signal sequence can mediate cotranslational ER targeting when located at the N-terminus of PrP or heterologous proteins (Gu et al., 2008) .
The structured C-terminal domain
Structural studies on recombinant PrP indicated a particular modular composition ( Figure 1A ): the N-terminal domain of Figure 1 . (A) Schematic presentation of the mammalian prion protein. ER-SS: ER signal sequence, α1-3: α-helical regions, β1, 2: β-strands, CHO: N-linked glycosylation acceptor site, GPI-SS: GPI anchor signal sequence, straight line: unstructured regions. Gray boxes mark domains implicated in the import of PrP into the ER. (B) The C-terminal structured domain is necessary and sufficient for effcient translocation into the ER. The scheme illustrates the ER import efficiency of different PrP mutants with deletions in the C-or N-terminal domain. While a deletion of the unstructured N-terminus and/or of the C-terminal GPI anchor signal sequence (PrP∆GPI, PrP∆N∆GPI) does not impair translocation of PrP the import efficiency successively decreased by increasing the deletions in the C-terminal structured domain.
PrP spanning 120 amino acids is flexibly disordered followed by a highly structured C-terminal domain of approximately 110 amino acids. This autonomously folding domain contains three α-helical regions and a short, two-stranded β-sheet (Donne et al., 1997; Riek et al., 1996; Riek et al., 1997) . The analysis of PrP-W145Stop, a pathogenic PrP mutant linked to Gerstmann-Sträussler-Scheinker syndrome in humans, provided the first hint that a loss of the C-terminal domain interferes with ER import of PrP: PrP-W145Stop was found in the cytosolic and nuclear compartment (Zanusso et al., 1999) . Further studies including a different pathogenic mutant, PrP-Q160Stop, corroborated these findings and revealed that information in the C-terminal domain of PrP is necessary and sufficient for its import into the ER (Heske et al., 2004) . We could now show that it is the presence of alpha-helical domains in the C-terminus that promotes ER import of PrP. The study revealed that after targeting to the translocon the secondary structure of the nascent polypeptide chain can significantly modulate translocation efficiency. ER-targeted polypeptides dominated by unstructured domains failed to efficiently translocate into the ER lumen and were subjected to proteasomal degradation via a co-translocational/pre-emptive pathway (Miesbauer et al., 2009 ).
Toxic PrP conformers in the cytosol

cytoPrP
A convincing model to demonstrate the neurotoxic capacity of cytosolically localized PrP (cytoPrP) was initially generated by Lindquist and coworkers: Mice expressing a PrP mutant with a deleted N-terminal ER targeting signal sequence acquire severe ataxia due to cerebellar degeneration (Ma et al., 2002) . Importantly, in a different transgenic mouse model toxicity of cytoPrP was also demonstrated in other neuronal populations (Wang et al., 2009) . Cell culture studies indicated that toxicity of cytoPrP seems to be dependent on its association with intracellular membranes (Wang et al., 2006) and its binding to Bcl-2, an anti-apoptotic protein present at the cytosolic side of ER and mitochondrial membranes (Rambold et al., 2006) . Brain extracts from clinically ill transgenic mice expressing cytoPrP do not contain infectious prions, a phenomenon also seen in other transgenic mouse models of neurotoxic PrP mutants (rev. in . In this context it should also be noted that cytosolically localized PrP seems to be present in a subset of neurons even under physiological conditions (Mironov et al., 2003) .
PrP Sc
The scrapie-prion protein or PrP Sc was originally identified as a protease-resistant protein in brain extracts that copurifies with the infectious scrapie agent (Bolton et al., 1982) . In contrast to PrP C , PrP Sc is insoluble in non-ionic detergents, partially resistant to proteolytic digestion and characterized by a high content of β-sheet secondary structure (Caughey et al., 1991; Meyer et al., 1986; Pan et al., 1993) . While PrP Sc seems to be sufficient for the formation of infectious prions, elegant grafting experiments provided the first evidence that PrP Sc is not toxic to neurons lacking PrP C , a finding later supported by conditional cell-type specific PrP knockout mice (Mallucci et al., 2003) and transgenic mice expressing PrP∆GPI, an anchorless PrP mutant (Chesebro et al., 2005) . We have recently established a new cell culture model, which corroborates the observations from the mouse models and supports the notion that PrP Sc is only toxic to cells expressing PrP C (Rambold et al., 2008) . Based on these findings, two plausible scenarios for the toxic effects of PrP Sc can be envisaged, which are not mutually exclusive: Either neurotoxicity of PrP Sc is linked to its propagation in neuronal cells, which is dependent on the expression of PrP C , and/or PrP Sc elicits a deadly signal through a PrP Cdependent signaling pathway. Employing mouse models, cell culture and in vitro approaches, Tabrizi and colleagues provided support for the notion that during a prion infection misfolded PrP can translocate into the cytosol of the infected cells and induce toxic effects by inhibiting the proteasome (Kristiansen et al., 2007) .
ER-targeted PrP can be re-directed to the cytosol via a co-translocational pathway
The cytosolic localization of ER proteins is usually linked to a cellular quality control system involving retrograde transport and subsequent proteasomal degradation, designated ERassociated degradation (ERAD). This pathway is designed to ensure cellular homeostasis and to preclude toxic effects of aberrant protein conformers within the ER. The accumulation of PrP in the cytosol after prolonged inhibition of proteasomal activity was initially interpreted as evidence for retrograde transport of PrP C from the ER lumen into the cytosol (Ma and Lindquist, 2001; Yedidia et al., 2001 ). This conclusion, however, was discussed controversially after cytosolic accumulation of PrP has been proposed to be an experimental artifact, due to the prolonged treatment of cells with proteasomal inhibitors and overexpression of PrP driven by a viral promotor (Drisaldi et al., 2003) . Based on our studies in yeast and mammalian cells we proposed that impaired ER import rather than retrograde translocation from the ER is responsible for the formation of cytosolic PrP Heske et al., 2004; Tatzelt and Winklhofer, 2004) (Figure 1B ). This concept was substantiated by recent studies showing that in addition to ERAD a co-translocational or pre-emptive quality control pathway exists, which interferes with the translocation of secretory pathway proteins into the ER lumen (Kang et al., 2006; Oyadomari et al., 2006) . As a consequence, such a co-translocation quality control pathway reduces the amount of non-native substrates in the ER lumen and thereby unburdens the luminal ER quality control machinery. This could be particularly beneficial under conditions of ER stress in order to reduce the ER protein folding load (Kang et al., 2006) . Support for the idea that PrP is targeted via a cotranslocational pathway to the cytosol was the observation that the cytosolic PrP fraction contained an uncleaved signal peptide (Heske et al., 2004; Miesbauer et al., 2009; Rambold et al., 2006; Zanusso et al., 1999) . Processing of the N-terminal signal peptide and the transfer of core glycans occur co-translocationally prior to the release of the polypeptide into the ER lumen (rev. in (Kornfeld and Kornfeld, 1985) . Thus, an uncleaved signal peptide is indicative for an abrogated translocation event. Interestingly, an uncleaved signal peptide was also described for Ctm PrP (Kim and Hegde, 2002; Stewart et al., 2001) . Moreover, it has been shown that an uncleaved signal peptide is a Targeting of the Prion Protein to the Cytosol 113 characteristic feature of other substrates subjected to the co-translocational/pre-emptive pathway (Oyadomari et al., 2006; Rutkowski et al., 2007) .
Why is it interesting that PrP seems to be subjected to a co-translocational quality control pathway? Little is known about quality control pathways of non-native or misfolded GPI-anchored proteins and ERAD in mammalian cells has mainly been studied with transmembrane proteins. Indeed, experimental evidence suggests that PrP is a poor ERAD substrate. In particular, PrP lacking a GPI anchor is misfolded and incompletely glycosylated, however, it is efficiently transported through the secretory pathway and finally secreted (Blochberger et al., 1997; Chesebro et al., 2005; Rogers et al., 1993; Walmsley et al., 2001; Winklhofer et al., 2003) . This observation suggests that PrP∆GPI is not sensed as misfolded by the cellular quality control systems in the ER lumen. Two observations support such a hypothesis. Firstly, the terminal glucose residues are removed from the core glycans of PrP∆GPI and secondly, even the overexpression of PrP∆GPI does not result in the activation of the unfolded protein response (UPR) . A recent study supports the idea that misfolded conformers of PrP generated in the ER lumen are neither recognized by ER quality control pathways nor routed to ERAD. Instead, mutant PrPs trafficked to the Golgi, from where the misfolded subpopulation was selectively trafficked for degradation in acidic compartments (Ashok and Hegde, 2009) .
Which conditions might impair the import of PrP into the ER? Regarding the ER import mechanism, it is important to note that translocation of PrP into the ER seems to be more complex than that of other secretory proteins. In vitro studies using reconstituted lipid vesicles revealed that ER import of PrP requires the translocon-associated protein (TRAP) complex in addition to the essential translocon components Sec61 complex, the signal recognition particle receptor and the translocating chain associated protein (TRAM) (Fons et al., 2003) . Consistent with the idea that an imbalance of cellular homeostasis brings a co-translocational quality control pathway on the scene (Rutkowski et al., 2007) PrP is translocated into the ER lumen. During import the N-terminal signal peptide is cleaved off and two N-linked glycans are attached. Shortly after release into the ER lumen the C-terminal signal sequence is removed and replaced with a preformed GPI anchor. During transit through the secretory pathway the core glycans are converted into complex structures and PrP C is finally targeted to the outer leaflet of the plasma membrane. In scrapie-infected cells, PrP C at the cell surface or along the endocytic pathways interacts with and is converted into PrP Sc . 2: The classical ERAD pathway would involve retrotranslocation of non-native or misfolded conformers of PrP present in the ER lumen into the cytosol. The N-linked glycans are removed by a cytosolic N-glycanase prior to proteasomal degradation. 3: In a co-translocational quality control pathway productive translocation of the growing polypetide chain into the ER is not pursued. Instead the protein is directly targeted to proteasomal degradation. Proteins subjected to this pathway would retain their N-terminal signal peptide. 4: In scrapieinfected cells oligomeric species of PrP Sc might translocate from the plasma membrane or endocytic compartments to the cytosol where they interfere with proteasomal activity.
Pathophysiological consequences of cytosolically localized PrP
A transgenic mouse model and various cell culture approaches provided convincing evidence that cytosolic PrP can have a toxic potential, however, two major questions have remained unanswered. First, does cytosolic PrP play a role in the pathogenesis of prion diseases and second, how does PrP in the cytosol induce neuronal cell death?
In this context it is important to remember that cytoPrP is biochemically quite different from infectious PrP Sc . CytoPrP does adopt a misfolded and partially proteinase K (PK)-resistant conformation, however, it lacks posttranslational modifications, like the GPI anchor and N-linked carbohydrates. Moreover, it does not seem to be infectious. A similar biochemical signature was described for PrP∆GPI. However, PrP∆GPI is efficiently imported into the ER and has no toxic activity in cultured cells (Rambold et al., 2006) nor does it cause neurodegeneration in transgenic mice (Chesebro et al., 2005) . Based on these findings we established a cell culture model to identify cellular components linked to the toxic activity of cytoPrP (Rambold et al., 2006) . Interestingly, an interaction of PrP and Bcl-2 was described previously for recombinantly expressed proteins Morgan, 1995, 1996) . We could verify such an interaction in neuronal cells and showed that the recruitment of Bcl-2 to misfolded PrP provides a plausible explanation for the toxic potential of cytoPrP (Rambold et al., 2006) . A different study revealed that toxicity of cytoPrP seems to be dependent on its association with intracellular membranes (Wang et al., 2006) , the locale where Bcl-2 resides. Regarding the role of Bcl-2 in cytoPrPmediated toxicity, two scenarios are conceivable. Bcl-2 may be inactivated by its sequestration into cytoPrP aggregates. In support of this possibility, recent results from our group indicated that cytoPrP can displace Bax from a Bcl-2/Bax complex (Rambold et al, unpublished results) . Alternatively, binding of Bcl-2 to cytoPrP may induce a conformational change of Bcl-2, converting it into a pro-apoptotic protein.
Evidence for opposing phenotypes of Bcl-2 was provided by Lin et al., who showed that the interaction with Nurr77 converts Bcl-2 from a protector to a killer protein (Lin et al., 2004) .
Two additional findings need to be considered in the context of cytoPrP-induced toxicity. First, binding of Bcl-2 to PrP, as well as the toxic potential of cytoPrP could be mitigated by the increased expression of Hsp70 and its cochaperone Hsp40, indicating a protective role of chaperones in PrP-induced toxicity (Rambold et al., 2006) . Second, several cell culture models indicated that toxicity of cytoPrP is markedly enhanced under conditions of proteasomal impairment, suggesting that under physiological conditions the accumulation of cytoPrP is efficiently controlled (Ma et al., 2002; Rambold et al., 2006; Rane et al., 2004; Wang et al., 2005; Yedidia et al., 2001 ). This multifaceted influence on the formation and clearance of cytoPrP, which seems to be highly dependent on the cellular homeostasis, provides a plausible explanation for the discrepant findings in different reports on the toxic potential of cytosolic PrP (Fioriti et al., 2005; Roucou et al., 2003) . In a different study it was shown that both Ctm PrP and cytoPrP can interact with and disrupt the function of Mahogunin, a cytosolic ubiquitin ligase whose loss causes spongiform neurodegeneration in mice (Chakrabarti and Hegde, 2009 ).
Interestingly, it was proposed that PrP Sc might also exert its toxic potential in the cytosol.Tabrizi and colleagues showed that β-sheet-rich conformers of recombinant PrP and semi-purified PrP Sc from prion-infected mouse brains inhibited the 26S proteasome in vitro. Moreover, proteasomal activity was decreased in prion-infected cells and in scrapiediseased mouse brain (Kristiansen et al., 2007) . This study not only might help to unravel pathophysiological mechanisms in prion diseases, it also supports the notion that oligomeric species rather than larger amyloid fibrils are the harmful species, a concept that was previously suggested for different neurodegenerative diseases (rev. in (Caughey and Lansbury, 2003; Haass and Selkoe, 2007) . It will now be interesting to see how oligomeric PrP Sc might translocate into the cytosol of scrapie-infected cells and how proteasomal impairment contributes to neuronal cell death in human prion diseases.
Future directions
To elucidate the mystery of a self-propagating protein conformer causing transmissible neurodegenerative diseases is a challenging mission, however, research on the prion protein has even more to offer. Transgenic mouse models paved the way for the intriguing concept that the infectious particle and the neurotoxic agent in prion diseases might be two distinct species. The existence of discrete conformers would also explain the phenomenon of sub-clinical prion infection (Hill et al., 2000) . The question remains whether neurodegenerative diseases induced by neurotoxic PrP mutants in the absence of infectious prion propagation are genuine models for naturally occurring prion diseases. However, the established animal and cell culture models are extremely valuable to address an essential question in neurodegenerative disease research: How do aberrant protein conformers activate toxic signaling pathways in neuronal cells?
In addition to disease-related features, basic research on the prion protein provided new insight into cellular pathways of general interest. For example, studies employing PrP helped to reveal that the ribosome-nascent chain complex attached to the translocon complex is more dynamic than previously appreciated and that a co-translocational regulation of ER import provides an effcient mechanism to control loading of the ER with secretory pathway proteins. After all, understanding the cellular biology of diseaseassociated proteins is the essential prerequisite to exlore pathomechanistic events and to develop new therapeutic strategies.
